TherapeuticsMD® Announces Third Quarter 2020 Financial Results

    0
    57

    Significant growth in net revenue, net revenue per unit and prescriptions across product portfolio Total net revenue increased 80% to $19.3 million compared to 2Q20 ANNOVERA ® net revenue increased 250% for 3Q20 compared to 2Q20 Menopausal products achieved double digit growth in new and total

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here